Canada could get a shipment of J&J vaccine in June amid quality concerns


Canada could receive shipment of 300,000 Johnson & Johnson COVID-19 vaccines by the end of this month.

During a COVID-19 press conference on Friday, Joelle Paquette, director general of vaccine procurement for Public Services and Procurement, Canada said that the country will receive a shipment from the United States by the end of June, but “more details will be provided.” as soon as we have solidified this. “

It is currently unclear whether the shipment came from the same U.S. facility that shipped the first batch of 310,000 Johnson & Johnson shots to Canada and was held back due to quality control issues.

“We have the 310,000 [doses] those that came earlier, that are still on hold pending approval by Health Canada. you [U.S.] announced that they will have a shipment by the end of this month, but more details will be announced as we consolidate this, ”said Paquette.

The story continues under the advertisement

The announcement comes when the EU and the US FDA decide to discard batches of the vaccine due to contamination concerns.

The European Medicines Agency announced on Friday that as a precautionary measure, batches of Johnson & Johnson’s COVID-19 vaccine made for the region at the time contamination issues were revealed at a U.S. manufacturing facility would not be used.

The announcement came after a report in the New York Times that said the U.S. Food & Drug Administration had asked Johnson & Johnson to ditch 60 million doses of its COVID-19 vaccine that was being made at the troubled factory in Baltimore were manufactured.

Continue reading:

US states urged to seek longer shelf life for J&J vaccines as millions are close to expiring

The European Medicines Agency (EMA) didn’t disclose how many syringes were affected, but Reuters has reported that the doses are millions, making it harder for J&J to hit the target of 55 million by the end of June Deliver to Europe.

Johnson & Johnson did not immediately respond to Reuters inquiries.


Click to play the video: “Is There Really a Preferred Vaccine?  NACI under fire after new guidelines conflict with previous advice


2:16Is There Really a Preferred Vaccine? NACI under fire after new guidelines conflict with previous advice


Is There Really a Preferred Vaccine? NACI under fire after new guidelines conflict with previous advice – May 4, 2021

The EMA announced that a batch of the compound for the COVID-19 vaccine from Johnson & Johnson was contaminated in April with materials for another vaccine manufactured at the Maryland site owned by Emergent Biosolutions.

The story continues under the advertisement

Production of the Johnson & Johnson vaccine on site has been discontinued by US authorities and Johnson & Johnson has been contracted to manufacture it at the facility.

The U.S. Food and Drug Administration is close to approving approximately 10 million doses of the vaccine made at the facility, CNN reported on Friday.

Continue reading:

US will resume use of J&J COVID-19 vaccine after CDC recommends ending the hiatus

The April bug related to ingredients from AstraZeneca’s COVID-19 vaccine, also manufactured at the facility, which contaminated a batch of Johnson & Johnson’s vaccine developed by the Janssen unit.

The EMA said the batch was not intended for the European Union and that, based on the information it had, batches of the vaccine released in the region were not affected by the cross-contamination.

– With files from Reuters

Show link »

© 2021 Global News, a division of Corus Entertainment Inc.



Source link